The FDA has granted Breakthrough Device Designation to Valar Labs’ Vesta Bladder Risk Stratify Dx, the first AI-powered digital pathology prognostic test for bladder cancer.
Read More
The FDA has cleared ArteraAI Breast, an AI-based digital pathology tool that provides same-day risk stratification for early-stage, HR-positive, HER2-negative invasive breast cancer.
Read More
Artera has received CE marks under EU IVDR for its AI-powered prostate and breast cancer assays, enabling clinical use of these prognostic and predictive tests in the European Union and other territories, the company announced.
Read More
The NCCN now recommends comprehensive molecular profiling for all pancreatic cancer patients eligible for therapy, regardless of stage, to better guide targeted treatment and clinical trial enrollment.
Read More
City of Hope will evaluate Quest Diagnostics’ Haystack MRD liquid biopsy in a multi-year trial, assessing its use for monitoring breast, colorectal, ovarian, and prostate cancers in about 500 patients across 14 US sites.
Read More